10-Q: Cyanotech Reports Q3 2025 Financial Results: Sales Up, Losses Narrowed

Cyanotech reports a 10.6% increase in net sales for Q3 2025, with reduced operating losses compared to the previous year.

Summary

• Cyanotech Corporation reported its financial results for the third quarter and first nine months of fiscal year 2025, which ended on December 31, 2024.
• Net sales for the third quarter of fiscal 2025 increased by 10.6% to $6.172 million, compared to $5.582 million for the third quarter of fiscal 2024.
• The gross profit margin for the third quarter of fiscal 2025 was 35.3%, with a gross profit of $2.179 million, compared to a gross profit margin of 29.5% and a gross profit of $1.649 million for the same period last year.
• The operating loss for the third quarter of fiscal 2025 was $50,000, compared to an operating loss of $848,000 in the same period of the prior year.
• The net loss for the current fiscal quarter was $224,000, or $0.03 per diluted share, compared to a net loss of $1.020 million, or $0.16 per diluted share, for the same period of the prior year.
• Net sales for the first nine months of fiscal 2025 increased by 4.8% to $17.915 million, compared to $17.101 million for the same period in fiscal 2024.
• The gross profit margin for the first nine months of fiscal 2025 was 28.7%, with a gross profit of $5.134 million, compared to a gross profit margin of 30.8% and a gross profit of $5.270 million for the same period last year.
• The operating loss for the first nine months of fiscal 2025 was $2.066 million, compared to an operating loss of $2.689 million in the same period of the prior year.
• The net loss for the first nine months of fiscal 2025 was $2.576 million, or $0.37 per diluted share, compared to a net loss of $3.186 million, or $0.50 per diluted share, for the same period of the prior year.
• For the trailing twelve months ended December 31, 2024, net sales were $23.885 million, compared to $22.492 million for the trailing twelve months ended December 31, 2023.
• The gross profit margin for the trailing twelve months ended December 31, 2024 was 24.3%, with a gross profit of $5.810 million, compared to a gross profit margin of 29.6% and a gross profit of $6.656 million for the same period last year.
• The net loss for the trailing twelve months ended December 31, 2024 was $4.657 million, or $0.66 per diluted share, compared to a net loss of $4.616 million, or $0.72 per diluted share.

Sentiment

Score: 7

Explanation: The sentiment is cautiously optimistic. While sales are up and losses have narrowed, the company still faces challenges in its packaged sales and relies on related-party financing. The management's comments reflect a cautious approach, acknowledging both progress and ongoing concerns.

Positives

• Net sales increased by 10.6% for the third quarter of fiscal year 2025.
• Gross profit margin increased to 35.3% for the third quarter of fiscal year 2025.
• Operating loss decreased significantly for the third quarter of fiscal year 2025.
• Net loss per share improved for the third quarter of fiscal year 2025.
• Net sales increased by 4.8% for the first nine months of fiscal year 2025.
• Operating loss decreased for the first nine months of fiscal year 2025.
• Net loss per share improved for the first nine months of fiscal year 2025.

Negatives

• The company still experienced a net loss of $224,000 in Q3 2025.
• The company still experienced an operating loss of $50,000 in Q3 2025.
• Gross profit margin decreased from 30.8% to 28.7% for the first nine months of fiscal 2025 compared to the same period last year.
• The company still experienced a net loss of $2.576 million for the first nine months of fiscal year 2025.
• The company still experienced an operating loss of $2.066 million for the first nine months of fiscal year 2025.

Risks

• Changes in sales levels to the company's largest customers could impact financial results.
• Weather patterns in Hawaii can affect production.
• Production problems can disrupt operations.
• New products carry inherent risks.
• Foreign exchange fluctuations can impact financial performance.
• Availability of financing is crucial for operations.
• National and global political, economic, business, competitive, market, and regulatory conditions can affect the company.

Future Outlook

The company's strategic direction is to position itself as a world leader in the production and marketing of high-value natural products from microalgae, focusing on stabilizing production volume, rationalizing market channel participation, and leveraging core competencies. The company will continue to emphasize its Nutrex Hawaiian consumer products while exploring further opportunities for bulk sales orders for Spirulina and Astaxanthin, both domestically and internationally. Extraction services to third-party customers are expected to generate additional income throughout the year.

Management Comments

• Matthew K. Custer, Cyanotech's President and Chief Executive Officer, stated that he is pleased by the continued progress in the third quarter, with a 10.6% increase in net sales.
• Matthew K. Custer also noted that the focus on inventory management and strategic restocking has allowed the company to meet demand more effectively, and the increase in gross profit to 35.3% reflects the positive results of those efforts.
• Matthew K. Custer mentioned that while bulk sales are helping drive growth, addressing the slower growth of packaged sales remains a priority, and the company remains focused on navigating these challenges and proceeding cautiously as they enter the next quarter.

Industry Context

Cyanotech operates in the dietary supplements market, specifically focusing on microalgae-based products like astaxanthin and spirulina. The company's performance is influenced by factors such as consumer demand for natural products, competition from other producers, and regulatory conditions. The company's emphasis on quality and sustainability aligns with growing consumer preferences in the health and wellness sector.

Comparison to Industry Standards

• It is difficult to compare Cyanotech's results directly to industry standards without specific data on competitors focusing on microalgae-based products.
• However, the company's gross profit margin of 35.3% in Q3 2025 can be benchmarked against other dietary supplement companies.
• Companies like Nutraceutical International Corporation and Nature's Sunshine Products typically have gross profit margins ranging from 30% to 40%.
• Cyanotech's focus on direct-to-consumer sales through its website www.nutrex-hawaii.com is a common strategy in the industry, similar to companies like iHerb and Vitamin Shoppe.
• The company's reliance on a related party for financing is not uncommon in smaller companies but may raise concerns about potential conflicts of interest.

Related Party Transactions

• The company has a loan facility with a related party that allows it to borrow up to $4.0 million on the Revolver.
• At December 31, 2024 and March 31, 2024, the balance on the Revolver was $2,750,000 and $1,250,000, respectively.
• In April 2019, the company obtained a loan in the amount of $1.5 million from a related party.
• As of both December 31, 2024 and March 31, 2024, the company had $1.0 million outstanding on the related party note.

Stakeholder Impact

• Shareholders: The improved financial results, particularly the increase in sales and reduction in losses, are positive for shareholders.
• Employees: The company's efforts to stabilize production and manage costs could impact employment levels and compensation.
• Customers: The company's focus on quality and sustainability is likely to benefit customers who value these attributes.
• Suppliers: The company's inventory management and production plans could affect its relationships with suppliers.
• Creditors: The company's debt levels and compliance with covenants are important factors for creditors.

Next Steps

• The company will host a virtual broadcast on February 12, 2025, to answer questions about its operating results.
• The company will continue to focus on stabilizing production volume, rationalizing market channel participation, and leveraging core competencies.
• The company will continue to emphasize its Nutrex Hawaiian consumer products while exploring further opportunities for bulk sales orders for Spirulina and Astaxanthin, both domestically and internationally.

Key Dates